missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Dihydroergotamine mesylate, Tocris Bioscience™

Description
Dihydroergotamine mesylate is a partial α-adrenergic agonist. Partial D2 dopaminergic receptor agonist. Competitive 5-HT antagonist.
Specifications
Specifications
| CAS | 6190-39-2 |
| Molecular Formula | C34H41N5O8S |
| MDL Number | MFCD00058615 |
| Quantity | 100 mg |
| Synonym | dihydroergotamine mesylate, dihydroergotamine methanesulfonate salt, dihydroergotoxine, prestwick_746, dihydroergotamine methanesulfonate salt, powder, dihydroergotamine mesilate, european pharmacopoeia ep reference standard, dihydroergotamine for peak identification, european pharmacopoeia ep reference standard, dihydroergotamine mesylate, united states pharmacopeia usp reference standard, 4r,7r-n-1s,2s,4r,7s-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo 7.3.0.0^ 2,6 dodecan-4-yl-6-methyl-6,11-diazatetracyclo 7.6.1.0^ 2,7 .0^ 12,16 hexadeca-1 15 ,9,12 16 ,13-tetraene-4-carboxamide; methanesulfonic acid, 6ar,9r-n-2r,5s,10as,10bs-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8h-oxazolo 3,2-a pyrrolo 2,1-c pyrazin-2-yl-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo 4,3-fg quinoline-9-carboxamide methanesulfonate |
| InChI Key | ADYPXRFPBQGGAH-UMYZUSPBSA-N |
| SMILES | CS(O)(=O)=O.CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O |
| IUPAC Name | (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carboxamide; methanesulfonic acid |
| Molecular Weight (g/mol) | 679.79 |
| PubChem CID | 6420006 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?